Big Pharma
19 November 2024 US Supreme Court blocks bid to overturn lower court ruling | District court found in 2023 that the generic would infringe patents owned by a Bausch subsidiary | Blockbuster drug Xifaxan is used to treat IBS with diarrhoea, and a liver-related brain disorder.
14 November 2024
12 November 2024
5 November 2024
31 October 2024
29 October 2024
24 October 2024
Latest Features
Asia
Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP.
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.
Europe
As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.
Big Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
Asia
Five cases in which preliminary injunctions were granted are examined by Takanori Abe of Abe & Partners.
Big Pharma
Life science attorneys should see some notable developments relating to artificial intelligence, patent eligibility and the Fintiv rule, write Manita Rawat and Alexander Stein of Morgan Lewis.
Asia
A Korean district court has applied a landmark ruling in a complicated vaccine dispute involving Pfizer, explain Young Kim, Yu-Seog WON, In Hwan Kim, and Amy Oh of Kim & Chang.
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills.
More News
22 October 2024 Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
22 October 2024 In-house pharma and biotech lawyers are taking on broader roles, from handling regulatory issues to corporate strategy—and outside counsel can help, finds Marisa Woutersen.
17 October 2024 At LSPN Fall North America, in-house counsel offered guidance on how to nail the perfect patent application. Marisa Woutersen reports.
17 October 2024 As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.
16 October 2024 UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.
10 October 2024 Duo successfully invalidate two CureVac patents in the UK | High Court deems patents invalid due to lack of inventive step and insufficient technical contribution | CureVac “disappointed” but stressed outcome does not affect ongoing litigation in Germany and US.
9 October 2024 Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox